Targeting T Cell Co-receptors for Cancer Therapy

Immunity. 2016 May 17;44(5):1069-78. doi: 10.1016/j.immuni.2016.04.023.


Checkpoint-blocking antibodies can generate potent anti-tumor responses by encouraging the immune system to seek and destroy cancer cells. At this time, the United States Food and Drug Administration has approved three checkpoint-blocking antibodies in three disease indications, and additional approvals are expected to broaden the clinical scope of immunotherapy. Herein, we review the clinical development of CTLA-4-, PD-1-, and PD-L1-blocking antibodies across tumor types and briefly discuss areas of active investigation of potential biomarkers.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Blocking / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • B7-H1 Antigen / immunology
  • CTLA-4 Antigen / immunology
  • Drug Approval
  • Humans
  • Immunotherapy / methods*
  • Lymphocyte Activation
  • Molecular Targeted Therapy
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Programmed Cell Death 1 Receptor / immunology
  • Receptors, Antigen, T-Cell / metabolism
  • Signal Transduction
  • T-Lymphocytes / immunology*


  • Antibodies, Blocking
  • Antibodies, Monoclonal
  • B7-H1 Antigen
  • CTLA-4 Antigen
  • Programmed Cell Death 1 Receptor
  • Receptors, Antigen, T-Cell